4th Apr 2016 07:00
Press Release | 4 April 2016 |
Quantum Pharma Plc
(the "Company")
Appointment of Joint Broker
Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce the appointment of N+1 Singer as the Company's Joint Broker, alongside Zeus Capital, with immediate effect.
- Ends -
For further information:
Quantum Pharma Plc |
| |
Andrew Scaife, Chief Executive Officer | Tel: +44 (0) 1207 279 404 | |
Chris Rigg, Chief Financial Officer | www.quantumpharmaplc.com | |
|
| |
Zeus Capital Limited (Nominated Adviser & Joint Broker) |
| |
Andrew Jones / Nick Cowles / Jamie Peel | Tel: +44 (0) 20 3829 5000 | |
Dominic Wilson / John Goold | www.zeuscapital.co.uk | |
|
| |
N+1 Singer (Joint Broker) |
| |
Aubrey Powell /James White/ Sandy Ritchie | Tel: +44 (0) 20 7496 3000 | |
Nick Owen / Brough Ransom
| www.n1singer.com | |
Media enquiries: |
| |
Buchanan |
| |
Henry Harrison-Topham / Sophie Cowles / Steph Watson | Tel: +44 (0) 20 7466 5000 | |
www.buchanan.uk.com | ||
Notes to Editors
Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions, offering a portfolio of innovative and complementary products and services.
Specials
Comprising four business units:
Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.
UL Medicines sources and supplies unlicensed imported medicines, batch-made and bespoke specials to hospitals, community pharmacies and wholesalers in the UK and overseas.
NuPharm offers outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines, product development as well as clinical trials product manufacture.
Quantum Aseptic Services manufactures aseptically prepared, sterile intravenous products, either individually, for named patients or in batches for supply to private and NHS hospitals and homecare patients.
Niche Pharmaceuticals
Comprising three business units:
Colonis® is a product development business, which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.
Lamda is a full-service contract development specialist with customers across Europe. It specialises in creating added-value products with distinct advantages for patients and health care providers. It also provides full services for the entire development chain - from inception to registration to post-approval, finished product supply and regulatory support.
PERN Consumer Products, owner of the Dermacool brand - a range of menthol in aqueous creams.
Medication Adherence
Comprising two business units:
Biodose® is a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence, for patients, their carers and clinicians. Biodose Connect® - a telehealth version with the ability to remotely monitor medication adherence is in live testing.
Biodose Services® assembles and delivers pre-prepared medication regimes to care homes and homecare patients, incorporating Biodose® as appropriate.
For further information, please visit www.quantumpharmagroup.com.
Related Shares:
Quantum Pharma